{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-242460","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2022-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.790483+00:00","generated_at":"2026-06-23T10:41:11.722681+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioMarin reports phase 3 BMN 270 patient diagnosed with leukemia; initial tests find no link to therapy","bullets":["BMN 270 phase 3 participant diagnosed with B-ALL; 85% of leukemic cells had Ph-like translocation.","BMN 270 vector DNA in leukemic cells was negligible (<1 copy per 500 cells), suggesting no clonal expansion.","No trial hold; all BMN 270 studies continue enrollment; DSMB agreed no modification needed.","BioMarin remains on track to resubmit BMN 270 BLA to FDA by end of September 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-242460","json":"https://secwatch.observer/filing/0001193125-22-242460.json","markdown":"https://secwatch.observer/filing/0001193125-22-242460.md","text":"https://secwatch.observer/filing/0001193125-22-242460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312522242460/0001193125-22-242460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312522242460/d306559d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T10:41:11.722681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}